GuayLA, MusokeP, FlemingTet al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 1999; 354:795–802.
2.
JacksonJB, MusokeP, FlemingTet al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet, 2003; 362:859–868.
3.
StringerJS, ZuluI, LevyJet al.Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA, 2006; 296:782–793.
4.
JourdainG, Ngo-Giang-HuongN, Le CoeurSet al.Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med, 2004; 351:229–240.
5.
LockmanS, ShapiroRL, SmeatonLMet al.Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med, 2007; 356:135–147.
6.
PitcherCJ, QuittnerC, PetersonDMet al.HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med, 1999; 5:518–525.
7.
SesterM, SesterU, KohlerHet al.Rapid whole blood analysis of virus-specific CD4 and CD8 T cell responses in persistent HIV infection. AIDS, 2000; 14:2653–2660.
8.
CasazzaJP, BettsMR, PickerLJ, KoupRA. Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol, 2001; 75:6508–6516.
9.
DalodM, DupuisM, DescheminJCet al.Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol, 1999; 73:7108–7116.
10.
GrayCM, LawrenceJ, SchapiroJMet al.Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)J Immunol, 1999; 162:1780–1788.
11.
KalamsSA, GoulderPJ, SheaAKet al.Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol, 1999; 73:6721–6728.
12.
MarkowitzM, VesanenM, Tenner-RaczKet al.The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis, 1999; 179:527–537.
13.
OggGS, JinX, BonhoefferSet al.Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol, 1999; 73:797–800.
14.
KuhnL, Meddows-TaylorS, GrayGet al.Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission. Clin Exp Immunol, 2001; 123:443–450.
15.
KuhnL, Meddows-TaylorS, GrayG, SchrammD, TiemessenCT. HIV-stimulated IL-2 production among exposed-uninfected infants of HIV-infected mothers given nevirapine prophylaxis. 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 10–14 February, 2003.
16.
SchrammDB, KuhnL, GrayGE, TiemessenCT. In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers. J Acquir Immune Defic Syndr, 2006; 42:545–553.
17.
ShalekoffS, Meddows-TaylorS, SchrammDBet al.Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women. J Acquir Immune Defic Syndr, 2008; 48:245–254.
18.
KuhnL, SchrammDB, DonningerSet al.African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine. AIDS, 2007; 21:1753–1761.
19.
SinghKK, HughesMD, ChenJet al.Associations of chemokine receptor polymorphisms with HIV-1 mother-to-child transmission in sub-Saharan Africa: Possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr, 2008; 49:259–265.
20.
KarpusWJ, LukacsNW, KennedyKJ, SmithWS, HurstSD, BarrettTA. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J Immunol, 1997; 158:4129–4136.
21.
YoshimuraT, MatsushimaK, TanakaSet al.Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA, 1987; 84:9233–9237.
22.
TakataH, TomiyamaH, FujiwaraM, KobayashiN, TakiguchiM. Cutting edge: Expression of chemokine receptor CXCR1 on human effector CD8+ T cells. J Immunol, 2004; 173:2231–2235.
23.
CoovadiaA, HuntG, AbramsEJet al.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis, 2009; 48:473–475.
